In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, with AstraZeneca revealing “encouraging data” out of its Phase I study of its obesity and diabetes drug AZD5004.…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.